Sareum (LON:SAR) Stock Price Up 13.2% – Here’s Why

Sareum Holdings plc (LON:SAR) was up 13.2% during mid-day trading on Friday . The company traded as high as GBX 15 ($0.20) and last traded at GBX 15 ($0.20). Approximately 467,324 shares were traded during trading, an increase of 3% from the average daily volume of 455,494 shares. The stock had previously closed at GBX 13.25 ($0.17).

Sareum Stock Up 16.4 %

The company has a 50 day moving average of GBX 16.74 and a 200 day moving average of GBX 22.62. The firm has a market cap of £19.26 million, a price-to-earnings ratio of -3.65 and a beta of -1.08.

Sareum (LON:SAR) last released its earnings results on Tuesday, March 25th. The company reported GBX (0.90) (($0.01)) EPS for the quarter. As a group, equities research analysts expect that Sareum Holdings plc will post -3.8 earnings per share for the current fiscal year.

Insider Transactions at Sareum

In other news, insider Stephen Parker bought 84,033 shares of Sareum stock in a transaction on Wednesday, March 26th. The shares were bought at an average price of GBX 12 ($0.16) per share, with a total value of £10,083.96 ($13,212.74). Insiders own 5.02% of the company’s stock.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.